I could answer that question.
Our products are second-line therapy. They're considered second-line therapy in the developing world. As mentioned, we're providing product to about 50,000 patients in this area. I think we work well with MSF, with UNICEF, and a variety of other organizations throughout the world.
We have a fixed dose combination: a full regimen--one pill once a day--that we've co-developed with Merck. We're making that available through our access program in all these countries, and this is available from us today.